Karahatay Serdar, Thomas Kesha, Koybasi Serap, Senkal Can E, Elojeimy Saeed, Liu Xiang, Bielawski Jacek, Day Terry A, Gillespie M Boyd, Sinha Debajyoti, Norris James S, Hannun Yusuf A, Ogretmen Besim
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 173 Ashley Avenue, Charleston, 29425 SC, USA.
Cancer Lett. 2007 Oct 18;256(1):101-11. doi: 10.1016/j.canlet.2007.06.003. Epub 2007 Jul 9.
It has been documented previously that defects in the generation of C(18)-ceramide, a product of ceramide synthase 1 (CerS1), also known as longevity assurance gene 1 (hLASS1), play important roles in the pathogenesis and/or progression of HNSCC. However, whether altered levels of ceramide generation in HNSCC tumors have any clinical relevance remains unknown. In this study, the levels of endogenous ceramides were measured in tumor tissues of 45 HNSCC patients as compared to their normal tissues using high-pressure liquid chromatography/mass spectrometry (LC/MS), and then possible link between ceramide levels and the clinical parameters of HNSCC were examined. The data showed that the levels of C(16)-, C(24)-, C(24:1)-ceramides were significantly elevated in the majority of tumor tissues compared to their normal tissues, while the levels of only C(18)-ceramide were significantly decreased in HNSCC tumors, especially in tumor tissues of male patients. Importantly, it was also shown here that decreased C(18)-ceramide levels in HNSCC tumor tissues were significantly associated with the higher incidences of lymphovascular invasion, and pathologic nodal metastasis. Importantly, attenuation of C(18)-ceramide was also positively linked to the higher overall stages of the primary HNSCC tumors. Therefore, these data suggest, for the first time, that the defects in the generation/accumulation of C(18)-ceramide might have important clinical roles in HNSCC, especially in lymphovascular invasion and nodal disease.
先前已有文献记载,神经酰胺合酶1(CerS1,也称为长寿保障基因1,即hLASS1)的产物C(18)-神经酰胺生成缺陷在头颈部鳞状细胞癌(HNSCC)的发病机制和/或进展中起重要作用。然而,HNSCC肿瘤中神经酰胺生成水平的改变是否具有临床相关性仍不清楚。在本研究中,使用高压液相色谱/质谱法(LC/MS)测量了45例HNSCC患者肿瘤组织及其正常组织中内源性神经酰胺的水平,然后研究了神经酰胺水平与HNSCC临床参数之间的可能联系。数据显示,与正常组织相比,大多数肿瘤组织中C(16)-、C(24)-、C(24:1)-神经酰胺水平显著升高,而在HNSCC肿瘤中,仅C(18)-神经酰胺水平显著降低,尤其是男性患者的肿瘤组织。重要的是,本研究还表明,HNSCC肿瘤组织中C(18)-神经酰胺水平降低与淋巴管侵犯和病理淋巴结转移的较高发生率显著相关。重要的是,C(18)-神经酰胺的减少也与原发性HNSCC肿瘤的较高总体分期呈正相关。因此,这些数据首次表明,C(18)-神经酰胺生成/积累的缺陷可能在HNSCC中具有重要的临床作用,尤其是在淋巴管侵犯和淋巴结疾病方面。